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The Advanced Glycation and Lipoxidation End products (AGEs and ALEs) are a heterogeneous class of
compounds derived from the non-enzymatic glycation or protein adduction by lipoxidation break-down
products. The receptor for AGEs (RAGE) is involved in the progression of chronic diseases based on persistent
inﬂammatory state and oxidative stress. RAGE is a pattern recognition receptor (PRR) and the inhibition of the
interaction with its ligands or of the ligand accumulation have a potential therapeutic eﬀect. The N-terminal
domain of RAGE, the V domain, is the major site of AGEs binding and is stabilized by the adjacent C1 domain.
In this study, we set up an aﬃnity assay relying on the extremely speciﬁc biological interaction AGEs ligands
have for the VC1 domain. A glycosylated form of VC1, produced in the yeast Pichia pastoris, was attached to
magnetic beads and used as insoluble aﬃnity matrix (VC1-resin). The VC1 interaction assay was employed to
isolate speciﬁc VC1 binding partners from in vitro generated AGE-albumins and modiﬁcations were identiﬁed/
localized by mass spectrometry analysis. Interestingly, this method also led to the isolation of ALEs produced by
malondialdehyde treatment of albumins. Computational studies provided a rational-based interpretation of the
contacts established by speciﬁc modiﬁed residues and amino acids of the V domain. The validation of VC1-resin
in capturing AGE-albumins from complex biological mixtures such as plasma and milk, may lead to the
identiﬁcation of new RAGE ligands potentially involved in pro-inﬂammatory and pro-ﬁbrotic responses,
independently of their structures or physical properties, and without the use of any covalent derivatization
process. In addition, the method can be applied to the identiﬁcation of antagonists of RAGE-ligand interaction.
1. Introduction
Advanced Glycation and Lipoxidation End products (AGEs and
ALEs) are now widely studied not only as biomarkers of oxidative
stress but also because emerging data indicate their involvement as
pathogenic factors and/or as damaging intermediates in several
chronic diseases [1–3]. The identiﬁcation, characterization and quan-
tiﬁcation of AGEs and ALEs in diﬀerent physio-pathological conditions
represent an emerging need, not only to ﬁnd correlations with the onset
and progression of diseases, but also to better understand the pathways
dealing with their formation. From an analytical point of view,
identiﬁcation and characterization of AGEs and ALEs are very challen-
ging and, despite the fact that several recent papers have increased our
knowledge in this ﬁeld, a detailed proﬁle of these oxidation products is
far from being reached for several reasons. AGEs and ALEs are
chemically heterogeneous and this is due to the fact that, on one hand
they arise from several reactive carbonyl species (RCS) chemically
heterogeneous precursors which are formed by both lipid and sugar
oxidation, and on the other hand RCS can react with diﬀerent
nucleophilic sites through multiple reaction mechanisms leading to a
quite wide variety of reaction products including intra/intermolecular
cross-links [4]. As an example, glyoxal, which is formed both from
sugar and lipid oxidation, reacts with lysine, arginine and cysteine
residues forming at least 11 reaction products including 3 cross-linked
products.
Another aspect making the identiﬁcation of protein adducts a quite
complex matter is their presence in negligible amounts with respect to
the native protein and their instability both from a metabolic and
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chemical point of view [5].
Because of the above mentioned aspects, most of the analytical
methods so far proposed are based on a sample preparation procedure
aimed at isolating/enriching AGEs and ALEs from native proteins
followed by their identiﬁcation and characterization by oﬀ target LC-
MS approaches [6,7]. Molecular recognition/enrichment based on
immunoaﬃnity chromatography techniques is limited due to the
chemical diversity of the analytes. Trapping AGEs/ALEs by chemical
derivatization is also quite limited because most of the chemical
moieties characterizing AGEs/ALEs are not suitable to be derivatized
(not reactive), with the exception of the carbonyl group. Keto/aldehydic
groups, which are characteristic of some protein adducts, are not
contained in native proteins and they can be easily derivatized by using
hydrazine and oxyl-amine containing agents [8]. Suitable enrichment
columns targeting carbonyl functions have also been recently set-up
and are found eﬀective in separating carbonylated AGEs/ALEs from
biological matrices [9,10]. Carbonyl-based derivatization strategies
have been used in some recent papers and they currently represent
the state of the art procedure for identifying AGEs/ALEs in biological
matrices [11–13].
However, we believe that such a strategy allows the identiﬁcation of
only a small fraction of AGEs/ALEs. This is due to the fact that, despite
the carbonyl function being contained in most of the AGEs/ALEs
precursors (RCS), it disappears once it covalently reacts with proteins,
forming non-carbonylated reaction products. It should also be con-
sidered that protein carbonyls are still reactive and are quite unstable,
as recently demonstrated by Liebler [5]. As an example, Fig. 1 shows
the reaction pathways of malondialdehyde (MDA) and glyoxal with
proteins, two RCSs whose formation has been demonstrated in several
physio-pathological conditions [14]. MDA is in equilibrium with beta-
hydroxy-acrolein which is an alfa-beta-unsaturated aldehyde forming a
Michael adduct with nucleophilic sites such as lysine. N-propenal
lysine can react with other nucleophilic sites such as lysine or arginine,
forming cross-links that do not contain any carbonyl group or with
another acrolein moiety forming di-hydropiperidine derivatives.
Glyoxal is another example of aldehydic precursor which forms protein
adducts most of them not containing derivatizable carbonyl moieties
[4].
Based on such premises, we here propose a novel strategy of sample
preparation that permits the modiﬁed proteins to be captured on the
basis of their aﬃnity for the VC1 domain of RAGE, one of the receptors
that mediate their damaging biological eﬀects. AGEs and ALEs can
induce a damaging eﬀect through diﬀerent mechanisms such as loss of
protein function or regulation, protein polymerization and aggregation,
altered immune response and signaling due to activation of receptors
such as RAGE. RAGE is a type I transmembrane glycoprotein and a
member of the immunoglobulin (Ig) superfamily. It also shares
structural similarities with a family of cell adhesion molecules
(CAMs) [15]. RAGE-encoding gene (AGER) was originally isolated by
a screening of a bovine lung cDNA library with an oligonucleotide
probe based on the amino-terminal sequence of RAGE and the
expression of the RAGE cDNA allowed transfected cells to bind 125I-
AGE-albumin in a saturable and dose-dependent manner [16]. The
ectodomain of RAGE is formed by three domains; V, C1 and C2.
Although the recombinant V domain can be expressed in bacteria,
puriﬁed and refolded in vitro and is the binding site for some ligands of
RAGE, biochemical studies revealed that V and C1 form together a
single integrated domain (VC1) that is the binding site for the majority
of RAGE ligands [17–19]. We have shown in a previous report that
VC1 can be produced as an autonomous domain in the methylotrophic
yeast Pichia pastoris [20]. The glycosylation of VC1 and its secretion
into the culture medium confers high solubility and stability to the
protein, especially if compared to the protein expressed intracellularly
in E. coli [20].
The idea of the herein proposed strategy has been to set-up an
aﬃnity chromatography based on a RAGE-VC1 stationary phase able to
trap and then enrich/isolate modiﬁed proteins acting as RAGE ligands,
independently of the modiﬁed moiety. The advantage of such an
approach is that it is able to enrich functional AGEs and ALEs involved
in pro-inﬂammatory and pro-ﬁbrotic response through RAGE activa-
tion, independently of their structures and without the use of any
covalent derivatization process.
Fig. 1. Major pathways for the formation of the glyoxal-derived AGEs and of MDA-derived ALEs.
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2. Materials and methods
2.1. Strain and growth condition
E. coli DH5α strain was used for DNA manipulation. P. pastoris
KM71 strain (MutS, Arg+, His-) (Invitrogen) was used for the hetero-
logous expression of VC1-His-Strep. P. pastoris cells were routinely
propagated on plates of YPDA (1% yeast extract, 2% peptone, 2%
glucose and 2% agar) at 30 °C. To induce the expression of recombi-
nant proteins, His+ Muts cells were shifted from Glycerol-complex
Medium (MGY) (1% yeast extract, 2% peptone, 1% glycerol, 1.34%
YNB, 4×10−5% biotin) to Methanol-Ethanol complex Medium (MEMY)
(1% yeast extract, 2% peptone, 0.5% methanol, 0.7% Ethanol, 1.34%
YNB, 4×10−5% biotin). Cells were routinely grown in ﬂasks at 30 °C
under strong agitation and growth was monitored through the increase
in optical density at 600 nm (OD600).
2.2. Construction of the expression plasmid
The recombinant plasmid for the expression of VC1-His-Strep in P.
pastoris was obtained by cloning a XhoI-digested DNA fragment
encoding the protein of interest into the corresponding sites of pHIL-
S1 vector (Invitrogen). In this vector, the expression of the recombi-
nant protein is under the control of the inducible AOX1 promoter and
the sequence encoding VC1 is in-frame with the secretion signal of P.
pastoris PHO1 encoding an extracellular acid phosphatase. The
sequence of the primers used for the ampliﬁcation of the DNA fragment
were VCXhoIFOR (5′-agcatattcgactgactcgagctcaaaacatcacagcccg−3′)
and VC1-233His-StrepREV (5′-atcgtcgggctcactcgagCTAaccaccgaa
ctgcgggtgacgccaagcgctaccaccgctaccaccaccgctaccaccaccgtgatggt-
gatggtgatgggcgctcacaggctcccagacacg−3′) where the XhoI site is
underlined, the stop codon is in capitol letter, the sequence encoding
the Strep tag (AWRHPQFGG) is in bold, the sequence encoding the 6x
His tag is in italic and bold, the CDS of VC1 is in italic. The two tags are
separated in the product by a linker of sequence GGGSGGGSGGSA.
PCR was carried out using as a template pET-15b-VC1243, harbouring
the cDNA encoding the precursor of hRAGE, and primers ampliﬁed a
portion corresponding to the V and C1 domains (amino acid residues
23–243). PCR ampliﬁcation was carried out using the Phusion® Hot
Start High-Fidelity DNA Polymerase (New England Biolabs, NEB) and
the DNA fragment was puriﬁed using Geneclean Turbo for PCR kit
(QIAGEN). The PCR product and the pHIL-S1 vector were digested
with XhoI (NEB), gel-puriﬁed and ligated (Quick Ligation Kit, NEB).
After transformation of DH5α E. coli cells, clones with the properly
oriented insert were identiﬁed by colony PCR using a universal 5′-
AOX1 primer with VC1-233His-StrepREV and VCXhoIFOR with the
3′AOX1-primer. Recombinant plasmid DNA, named pHIL-S1-VC1-
His-Strep, was puriﬁed. The in-frame fusion and the absence of
random mutations in the insert were veriﬁed by DNA sequencing
(BMR Genomics, Padova, Italy). HIL-S1-VC1-His-Strep plasmid, lin-
earized with SalI, was transformed into KM71 P. pastoris cells using
the “EasyComp” chemical transformation method (Invitrogen) as
previously described [20].
2.3. Protein expression and puriﬁcation
To induce the expression of the recombinant protein, cells were
grown overnight at 30 °C in MGY under strong agitation and at a ratio
between volume of culture and capacity of the ﬂask of 1:10. Then, an
appropriate amount of cells was collected by centrifugation and cells
were suspended in methanol-ethanol-containing medium (MEMY) at
an initial OD600 of ~1. Growth was monitored by increase of OD600.
Fresh methanol was added daily to 0.5% (v/v) ﬁnal concentration. To
monitor protein expression, supernatants obtained by centrifugation of
1 ml-aliquots of culture, withdrawn at intervals after induction, were
ﬂash-frozen and stored at −20 °C for subsequent SDS-PAGE analyses.
Ten clones were screened to select the best producer.
In general, VC1-His-Strep was puriﬁed from the culture medium by
a single-step protocol. The culture supernatant was collected after 72 h
from induction by centrifugation of the culture at 4300×g for 15 min at
4 °C. The culture supernatant was ﬁltered (Nitrocellulose 0.22 µm) and
either frozen at −20 °C or immediately processed. If frozen, after
thawing at 4 °C the culture supernatant was ﬁltered again
(Nitrocellulose 0.22 µm). Appropriate aliquots from stock solutions
(3 M NaCl, 1 M HEPES and 1 M imidazole) were added to bring the
culture supernatant to the ﬁnal concentration of 300 mM NaCl, 20 mM
HEPES and 20 mM imidazole whereas pH was adjusted to 7.4 with
NaOH. The solution was applied on a HisPrep FF (16/10) Ni-
Sepharose Fast ﬂow column (GE Healthcare) connected to
AKTAprime plus and equilibrated with Buﬀer A (20 mM HEPES,
300 mM NaCl, 20 mM imidazole pH 7.4). The column was washed
with Buﬀer A until the A280 reached the base line and the protein was
eluted with a linear gradient of Buﬀer B (20 mM HEPES, 300 mM
NaCl, 1 M imidazole, pH 7.4). The fractions containing the puriﬁed
VC1-His-Strep were collected, analyzed by SDS PAGE and then
dialysed for 16 h at 4 °C against Buﬀer C (20 mM HEPES, 100 mM
NaCl pH 7.1).
2.4. Preparation of sugar-derived AGE- albumins
Bovine serum albumin (Fraction V, sterile ﬁltered, endotoxin-
tested, Cat no. A9576) and recombinant human serum albumin
(HSA) expressed in P. pastoris (Cat no. A7736) were obtained from
Sigma. AGE-serum albumins were obtained as described by Valencia
J.V. et al. [21]. The albumins were incubated with glucose for 3 months
or with ribose for one week. After incubation with the sugar and
removal of the unreacted sugar by diaﬁltration on Amicon Ultra- 0.5 ml
(Cut oﬀ 10 K), the ﬂuorescence emission spectra of 0.05–1 mg ml−1
AGE-BSA and control BSA was determined using a Fluorescence
Spectrofotometer (Varian, Cary Eclipse) at 380 nm excitation wave-
length with emission scan from 400 to 550 nm where a maximum of
emission intensity at approximately 440 nm was registered for AGE-
albumins.
2.5. In vitro generation of protein adducts by reactive carbonyl
species
Recombinant HSA was dissolved in phosphate buﬀer (10 mM
sodium dihydrophosphate NaH2PO4·H2O buﬀered with 200 mM dis-
odium phosphate Na2HPO4·2H2O to reach pH 7.4) at a concentration
equal to 100 μM (6.7 mg ml−1). Malondialdehyde (MDA) was pur-
chased from Sigma (Cat no. 63287). HSA was incubated at 37 °C in a
ﬁnal volume of 1 ml containing 500 μl of HSA 100 μM and MDA (stock
solution 1.26 M in phosphate buﬀer) at increasing concentrations
(315 μM, 3.15 mM, 31.5 mM, 315 mM, and 630 mM) corresponding
to protein: RCS molar ratios equal to 1:6.3, 1:63, 1:630, 1:6300, 1:
12,600, or an equal volume of phosphate buﬀer was added to HSA to be
used as a control untreated sample. The reactions were stopped after
24, 48 or 72 h by diluting the excess of RCS by ultraﬁltration, using
Amicon YM10 ﬁlter units (Millipore, Milan, Italy) as previously
described [22]. Samples were diluted to 0.125 mg ml−1 with Buﬀer C
and used for the pull-down assay.
2.6. Preparation of the VC1-resin
Puriﬁed VC1-His-Strep was immobilized on streptavidin-coated
magnetic beads by exploiting the aﬃnity of the Strep tag for
Streptavidin (Streptavidin Mag Sepharose™, GE Healthcare, cat. N.
28-9857-99). The binding capacity of the beads was 3 μg of VC1-His-
Strep/10 μl of medium slurry. In general, 50 μg of puriﬁed VC1-His-
Strep in 170 μl of buﬀer C were added to 5 μl of packed streptavidin
coated-beads previously obtained by washing 50 μl of 10% slurry with
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Buﬀer C, and incubated for 1 h at 4 °C on a rotary mixer at low speed.
The unbound material was carefully removed and the magnetic beads
were washed with 500 μl of buﬀer C and immediately used or stored at
4 °C. For simplicity, the VC1 bound to the beads is referred to as the
VC1-resin and the beads alone as the control resin.
2.7. VC1 pull-down assay
The VC1-resin was incubated for 1 h at 4 °C with 160 μl of AGE-
BSA or AGE-HSA or untreated BSA or HSA at the concentration of
125 μg ml−1 in buﬀer C. The unbound material was carefully removed
and the beads were washed twice with 500 μl of Buﬀer C. The elution
was performed by boiling the beads for 5 min in 15 μl of SDS Sample
Buﬀer 2X [0.125 M Tris-HCl, pH 6.8, 4% (w/v) SDS, 200 mM
dithiothreitol, 20% (w/v) glycerol and 0.02% Bromophenol blue] and
then with other 10 μl of the same buﬀer. The two eluates were pooled.
The control resin was treated in the same way to detect not speciﬁc
binding. The various fractions were analyzed by SDS-PAGE.
In a simulated complex biological mixture, we used milk treated as
follows: 5% (w/v) of dried skimmed milk powder was dissolved in
20 mM HEPES, 100 mM NaCl, pH 7.1, incubated at 95 °C for 5 min
and then ﬁltered (0.22 µm) to remove aggregates. AGE-BSA was used
to spike 160 μl of 5% milk at a ﬁnal concentration of 125 μg ml−1.
Serum was diluted to reach a protein concentration of about
0.8 mg ml−1. 160 μl of the diluted serum were spiked with AGE-BSA
at the same concentration as described above. In the pull-down assay of
albumins added to complex mixtures, Triton X-100 was added to
Buﬀer C at a ﬁnal concentration of 0.5%. The protein eluates were
resolved by SDS-PAGE.
2.8. Electrophoretic procedures
The fractions obtained from pull-down experiments were analyzed
by SDS PAGE. 20 μl of input, unbound and wash fractions were mixed
with 5 μl of SDS Sample Buﬀer 5X [0.312 M Tris-HCl, pH 6.8, 10% (w/
v) SDS, 500 mM dithiothreitol, 50% (w/v) glycerol and 0.05%
Bromophenol blue] and heated for 5 min at 99 °C. Samples, including
the eluate obtained as described in paragraph 2.7, were separated by
SDS-PAGE on any Kd pre-cast polyacrylamide gels (TGX, Bio-Rad) and
stained with Coomassie blue (Bio-Safe, Bio-Rad). Images were ac-
quired using the calibrated densitometer GS-800 and analyzed by the
software Quantity one (Bio-Rad).
2.9. AGE- and ALE-serum albumin digestion
Polypeptide bands corresponding to AGE-BSA, obtained by incuba-
tion with ribose or glucose, and ALE-HSA incubated with MDA and
retained by VC1, were excised from gels. After a brief wash with 100 μl
of 50 mM ammonium bicarbonate (Sigma Aldrich), gel pieces were
incubated with 10 mM dithiothreitol at 56 °C for 30 min and then with
55 mM iodoacetamide (Sigma Aldrich) at room temperature for 45 min
in the dark. In-gel digestion of AGE-BSA and ALE-HSA was performed
by overnight-incubation at 37 °C with 1 µg of sequencing-grade trypsin
(Roche) dissolved in 50 mM ammonium bicarbonate. ALE-HSA was
also subjected to a second digestion by a sequencing-grade chymo-
trypsin (1 µg) for 7 h at 25 °C in the presence of calcium chloride
(10 mM). Peptide mixtures were extracted by a 10 min-incubation with
extraction solution (acetonitrile/triﬂuoroacetic acid/water; 30/3/67; v/
v/v) and by an additional 10 min-incubation with 100% acetonitrile.
The two extracts were combined and dried in a vacuum concentrator
(Martin Christ.). Digested peptide mixtures were then dissolved in an
appropriate volume of 0.1% formic acid for mass spectrometry (MS)
analysis.
2.10. Mass spectrometry analyses
Five μl of solubilized peptides were loaded on a home-made nano-
column (PicoFrit 75 µm ID, 12 cm-long, New Objective) packed with
ReproSil-Pur 120 C18-AQ resin (1.9 µm, Dr. Maisch GmbH) by an
Easy-nLC 1000 (Proxeon) controlled by the software Xcalibur
(Thermo, version 3.1.66.10). Peptides were separated using a reverse
phase two-step gradient (from 10% to 70% acetonitrile in 0.1% formic
acid over 25 min) and on-line electrosprayed into a Q-Exactive mass
spectrometer equipped with a nanospray ion source (both Thermo).
The mass spectrometer operated in data dependent acquisition (DDA)
mode, controlled by the software Xcalibur to acquire both full MS
spectra in the m/z range 300–2000 (resolution 35,000 FWHM at m/z
200) and MS/MS spectra obtained by HCD of the 10 most abundant
multi-charged ions. Automatic gain control (AGC) was set at 3×106 for
the acquisition of full MS spectra and at 1×105 for MS/MS spectra. To
avoid redundancy, precursor ions already selected for fragmentation
were dynamically excluded for 15 s. Mono-isotopic precursor selection
was enabled; singly and unassigned charged ions were excluded from
fragmentation.
2.11. Identiﬁcation and localization of protein adducts
The software Proteome Discoverer (version 1.3.0.339, Thermo
Scientiﬁc, USA) was used to extract peaks from spectra and to match
them to the BSA sequence (Uniprot P02769) or HSA sequence (Uniprot
P02768). Trypsin or trypsin/chymotrypsin was selected as the cleaving
proteases, allowing a maximum of 3 missed cleavages. Peptide and
fragment ion tolerances were set to 5 ppm and 10 mmu, respectively.
Cys carbamidomethylation was set as ﬁx modiﬁcation (+57.02147).
Methionine oxidation was allowed as a variable modiﬁcation in
addition to several ribose-, glucose- or MDA-derived modiﬁcations
listed in Table S1. As a quality ﬁlter, only peptide matches with “high”
conﬁdence (FDR≤0.01) were considered as genuine peptide identiﬁca-
tions. For the localization of AGE/ALE-deriving modiﬁcations, the MS/
MS spectra of modiﬁed peptides were manually inspected; for the
conﬁdent mapping of the modiﬁcation site, spectra were requested to
match the expected ions (b and/or y) neighbouring the modiﬁed amino
acid both at the N- and C-termini.
2.12. Computational studies
To better investigate the key factors governing the interaction
between RAGE and its ligands, with particular attention to MDA-
induced adducts on HSA, a docking study was undertaken. The
recombinant HSA crystal structure was retrieved from PDB (Id:
4G03). Simulations focused on the monomer A that shows the higher
percentage of residues falling in the allowed regions of the
Ramachandran plot. In detail, the water molecules and the crystal-
lization additives were removed while the hydrogen atoms were added
and, to remain compatible with the physiological pH, arginine, lysine,
glutamate and aspartate residues were considered ionized by default.
The completed protein structure was then minimized keeping the
backbone atoms ﬁxed to preserve the resolved folding. The optimized
HSA was used to generate the experimentally detected MDA-induced
adducts, described in Dataset S1, by manually modifying the arginine
and lysine residues as listed in Table 3 using the VEGA suite of
programs [23]. The modiﬁed HSA structure was ﬁnally minimized by
keeping ﬁxed all atoms outside a 8 Å radius sphere around the
adducted residues and the optimized protein structure undertook to
following docking analyses.
Similarly, the resolved structure of the RAGE V-domain was
retrieved from PDB (Id: 2mov). This structure was chosen since it is
in complex with a hydroimidazolone adduct, thus allowing a precise
deﬁnition of the binding site to be used in the following docking
simulations [24]. Among the 20 reported NMR structures, that with the
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highest percentage of residues falling in the allowed regions of the
Ramachandran plot was utilized. The selected frame was then mini-
mized keeping the backbone atoms ﬁxed and then the included ligand
was deleted.
In order to simplify the calculations and to render them suitable
also for a screening of huge libraries of protein adducts, docking
simulations were focused on the protein environments of the adducted
residues as obtained by generating pseudo-ligand structures composed
of the adducted residue plus the neighbouring residues comprised
within a 5 Å radius sphere. For each adducted residue, the calculations
were repeated by considering the same surrounding sphere and the
residue with or without the detected modiﬁcation. The set of computa-
tional experiments is the subject of a manuscript submitted to Data in
Brief. Docking simulations were performed by PLANTS focusing the
search on a 12 Å radius sphere around the bound hydroimidazolone.
For each pseudo-ligand, 10 poses were generated and ranked by
ChemPLP score with a speed equal to 1 [25]. The best pose so obtained
were then optimized and utilized for rescoring analyses. All mentioned
minimizations were performed by using Namd with the CHARMM
force ﬁeld and the Gasteiger's atomic charges [26].
3. Results
3.1. Expression and secretion of VC1-His-Strep from Pichia pastoris
We expressed a recombinant form of VC1, named VC1-His-Strep,
in P. pastoris that previously proved to be a suitable host for the
expression and secretion of stable and soluble forms of VC1 domain
from human RAGE [20]. The C-terminal end of VC1 was fused to a 6 x
Histidine (His) tag and a Strep tag (AWRHPQFGG), separated by an
internal spacer. The tandem fusion was designed to facilitate the
puriﬁcation procedure by use of aﬃnity chromatography on Nickel-
chelating resins whereas the Strep tag was chosen for performing the
high-aﬃnity binding of the puriﬁed domain to Streptavidin-coated
beads.
The adoption of a mixed ethanol/methanol induction protocol,
described in Materials and methods, increased approximately 6 times
the yield of secreted VC1-His-Strep compared to the previously
protocol based on methanol alone [20]. At 72 h from the induction,
VC1-His-Strep accumulated in the medium as two major polypeptide
bands and the yield was about 45 mg liter−1 (Fig. 2A). One-step
puriﬁcation yielded homogeneous preparation of VC1-His-Strep with
negligible loss of protein ( < 5%). As shown in Fig. 2A and B, VC1-His-
Strep migrated as a doublet of two glycoforms, p36 and p34,
consistently with the diﬀerent degree of occupancy of two N-glycosyla-
tion sites, both occupied in p36 and occupied only at one site in p34, as
described previously for untagged VC1 [20]. Finally, gel ﬁltration
studies yielded VC1-His-Strep that eluted in a single sharp peak
corresponding to monomeric VC1 forms (data not shown). MS analysis
of gel-puriﬁed VC1-His-Strep demonstrated the identity of the protein
with the expected amino acid sequence, the proper removal of the
signal peptide and the presence of the tags with coverage of 76.25%.
3.2. Functional characterization of immobilized VC1
Puriﬁed VC1-His-Strep was immobilized via the Strep tag on
Streptavidin-coated magnetic beads and the derived VC1-resin was
used as bait in pull-down assays.
In order to test if VC1-resin captures AGEs, AGE-serum albumins
obtained after prolonged in vitro incubation with reducing sugars,
glucose or ribose, were used as preys in pull-down assays. Streptavidin-
coated magnetic beads alone were used as a control (control resin).
Optimal saline concentrations were determined by testing the eﬀect of
diﬀerent concentrations of NaCl (from 20 to 100 mM) in the binding
or/and washes. A concentration of 100 mM NaCl proved optimal for
speciﬁc binding (data not shown). Binding of AGE-BSA was performed
by incubating BSA obtained by reaction with glucose, called BSA-
Glucose (BSA-G), with the VC1- or control resin. After removal of the
unbound fraction and two washes, the complex formed by the bound
protein-VC1 and Streptavidin was dissolved by boiling the resin in
SDS-sample buﬀer. SDS-PAGE analysis of the eluates from the VC1-
resin and the control resin showed the binding of BSA-G to the VC1-
resin and no signiﬁcant interaction with the control resin (Fig. 3A). As
expected, streptavidin was present in the eluate from both the VC1-
resin and the control resin whereas VC1 was only present in the eluate
from the VC1-resin and not from the control resin (Fig. 3A). High
molecular weight (HMW)-species of BSA-G (≥250 kDa), likely repre-
senting cross-linked and highly modiﬁed species, were preferentially
retained by VC1.
We also tested AGE-BSA obtained by incubation with ribose (BSA-
R). Fig. 3B shows that VC1 enriches HMW-species present in the
sample. Untreated BSA was not retained by the VC1-resin and
migrated as a 66 kDa-polypeptide as expected for the unmodiﬁed
albumin (Fig. 3B). No binding of BSA-R was detected with the control
resin (data not shown). Additionally, recombinant human serum
albumin treated with ribose (HSA-R) gave similar results (Fig. 4). In
conclusion, VC1-resin speciﬁcally captures AGE-modiﬁed serum albu-
mins.
3.3. Characterization by MS of AGE products retained by VC1
To determine the type of modiﬁcations present in the molecular
species of AGE-BSA captured by the VC1 domain, a MS analysis of the
in gel-digested HMW bands was performed (Fig. 3A, lane E from VC1-
resin, bands ≥250 kDa). The localization of each modiﬁcation was
mapped in the amino acid sequence of BSA by using stringent criteria
to avoid false positive hits. Thus, only high-conﬁdence identiﬁcation
and mapping were taken into account. Table 1 shows that the most
modiﬁed residues were Lys256 (Schiﬀ base, deoxy-fructosyl- and
carboxymethyl-) and Lys437 (carboxymethyl-, deoxyfructosyl-) indicat-
ing that these sites are the most susceptible to modiﬁcations following
treatment of BSA with glucose.
Table 2 reports the modiﬁed peptides detected in HMW species of
Fig. 2. One-step puriﬁcation of VC1-His-Strep from the culture supernatant
of P. pastoris recombinant cells. (A) Culture supernatant was collected at 72 h after
ethanol/methanol induction of KM71-VC1-His-Strep cells and an aliquot (30 μl) was
directly analyzed by SDS-PAGE. (B) Secreted VC1-His-Strep (2 μg) was puriﬁed from the
culture supernatant by Nikel-aﬃnity chromatography. Proteins were separated by SDS-
PAGE and stained by Coomassie blue. Arrows indicate the two glycoforms of VC1-His-
Strep.
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AGE-BSA obtained by incubation with ribose and retained by VC1
(Fig. 3B, lane E from VC1-resin, bands ≥250 kDa). Ribose treatment
generated diﬀerent adducts. The most frequently modiﬁed residues
were: Lys235 (pyrraline and Schiﬀ base), Arg360 (carboxymethyl-, Schiﬀ
base and +218 modiﬁcation) and Lys437 (pyrraline, Schiﬀ base, +218
modiﬁcation and carboxyethyl-). Overall, Lys437 was particularly prone
to modiﬁcation by both sugars, indicating that is a highly reactive
residue as previously reported [27]. In this study, both Lys548 and
Arg360 were susceptible to modiﬁcations following treatment of BSA
with either one of the two sugars although the type of modiﬁcations
was diﬀerent (Tables 1 and 2). Interestingly, Lys548 of BSA corresponds
to Lys549 in HSA that was recently detected also in vivo as a target
residue of an AGE modiﬁcation in human serum albumin [28].
3.4. Capability of VC1 to capture modiﬁed albumins in complex
biological matrices
The VC1-interaction experiments described above show the speciﬁc
interaction of VC-resin with model AGE-proteins. To test the speciﬁcity
of VC1 binding in complex mixtures, we spiked AGE-serum albumins
in simulated biological samples such as milk and serum. The conditions
of the pull-down experiments were the same except that 0.5% Triton X-
100 was present in the binding and wash steps.
We spiked a solution of 5% milk with AGE-BSA. Fig. 5A shows that
VC1-resin speciﬁcally captures HMW-species of BSA-Ribose added to
milk. A similar experiment was performed using human serum. Fig. 5B
shows that AGE-HSA binds the VC1-resin in the presence of human
serum and not the control resin. Thus, the VC1-resin is able to capture
AGE-modiﬁed model proteins also in the presence of complex protein
mixtures.
3.5. Binding of ALEs to VC1
To further characterize the properties of VC1, we performed a time-
course analysis of HSA incubated with diﬀerent concentrations of MDA
expressed in molar ration of MDA to HSA of 6.3, 63, 630, 6300 and
12,600. At 24, 48 and 72 h, untreated and treated HSA samples were
assayed for binding to VC1-resins or to control resin. At 6.3 M ratio,
binding of HSA to VC1-resin was negligible (data not shown). At
increasing molar ratios and incubation time, higher amounts of HMW
HSA species (≥250 kDa) and of a form of ~70 kDa were eluted from the
VC1-resin but not from the control resin with a predominance of the
HMW species (Fig. 6).
To characterize the nature of the modiﬁcations induced by MDA,
the identiﬁed molecular species of HSA were subjected to in gel
digestions and MS analysis (Dataset S1). Further computational
studies based on these results are described in the next section.
Since MDA leads to the formation of ALEs, we can conclude that
VC1 retains ALE-HSA, suggesting that RAGE is also a receptor for
ALEs.
3.6. Computational results
Since interactions between RAGE and AGE have already been
investigated at an atomic level (see for example the resolved and here
utilized RAGE-AGE complex), we focused our attention only on the
interactions between RAGE and MDA-induced adducts especially
considering that this is the ﬁrst study reporting RAGE-ALE interac-
tions.
For each considered protein adduct and the corresponding un-
modiﬁed residue, Table 3 compiles some representative docking scores
plus the relative diﬀerences. In detail, Table 3 includes the ChemPLP
score that was utilized by the docking program, the knowledge-based
Fig. 3. Analysis of AGE-BSA binding by pull-down assay using the VC1-resin. (A) Same amounts of AGE-BSA obtained by incubation with glucose (BSA-G) were used as input
(IN). BSA-G was incubated with VC1 immobilized on the Streptavidin coated magnetic beads (VC1-resin) or with the Streptavidin-coated magnetic beads alone (control resin) as
indicated. The unbound fraction (UNB), the second wash after binding (W) and the eluate (E) from each resin are shown. The E fraction is obtained by boiling the resin with SDS-sample
buﬀer as indicated in Materials and methods and this step removes any associated molecule from the resin including the two forms of VC1 (p34 and p36), and Streptavidin (~14 kDa).
Note that VC1 forms were not present in the eluate from the control resin because VC1 was not immobilized on these beads. (B) AGE-BSA obtained by incubation of BSA with ribose
(BSA-R) or reagent-grade BSA were used as input (IN). Both samples were incubated with the VC1-resin and the unbound fraction (UNB) and eluate (E) were analyzed. Samples were
analyzed under reducing conditions by SDS-PAGE and stained with Coomassie blue. High MW- species of BSA-G or BSA-R are enriched by the pull-down assay with the VC1-resin and
no binding of unglycated BSA occurs on VC1-resin.
Fig. 4. Binding of AGE-HSA to the VC1-resin. Recombinant HSA obtained by
incubation in the presence (HSA-R) or absence of ribose (HSA), was used as input (IN).
Both samples were used in pull-down assays with the VC1-resin and the unbound
fraction (UNB) and eluate (E) were analyzed by SDS-PAGE, as described in Fig. 3. The
gel shows that High MW species of HSA-R are preferentially retained by the VC1-resin
whereas untreated HSA (66 kDa) does not bind VC1.
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XScore plus two scores useful to reveal the speciﬁc contribution of ionic
and non-ionic interactions, namely APBS which encodes for electro-
static contacts and LJ which encodes for van der Waals contacts as
computed by the Lennard-Jones equation of the CHARMM force ﬁeld.
The results concerning Lys65, Lys298, Lys499 and Arg281 are not
included in Table 3 since these residues are buried within protein
pockets and thus the adducted residues were unable to conveniently
approach the RAGE-VC1 surface. Gratifyingly, the compiled average
scores and relative diﬀerences reveal that the adducted residues show
better mean values in almost all considered scores compared to the
unmodiﬁed ones, suggesting that the obtained docking results are able
to rationalize the observed aﬃnity of MDA-modiﬁed HSA for RAGE.
When considering the speciﬁc scores, Table 3 reveals that the
complexes for the adducted residues are substantially stabilized by
ionic interactions, a result easily explainable considering that the
simulated protein adducts involve the neutralization of a positively
charged residue. Again, van der Waals contacts also play a clear
stabilizing role which can be explained considering that the formed
neutral adducts elicit non-ionic contacts with RAGE. When considering
the score values for each simulated adduct, one may observe that Lys75
and Arg361 are the ones which show the most marked enhancement
when comparing adducted and unmodiﬁed residues and focusing
attention on both ionic APBS score and comprehensive scores
(ChemPLP and XScore). Notably, the Arg361 adduct shows unfavour-
able van der Waals interactions, suggesting that here the ionic contacts
elicited by the neutralization of an arginine residue are so favourable as
to stabilize alone the complex.
In order to oﬀer a more detailed rationalization of the score proﬁles
reported in Table 3, Fig. 7 compares the putative RAGE complexes for
the two adducts aﬀording the best and the worst stabilizing eﬀect
(namely on Lys75 and Lys499), respectively. The reported stabilizing
contacts reveal that in both complexes the neutral adduct stabilizes
similar H-bonds with Lys32 and Gln80. Again, both complexes are
stabilized by ionic contacts involving Arg78 of RAGE. The key diﬀerence
which can explain the worst scores as computed for Lys499 concerns the
presence of Arg496 which is engaged in ionic repulsion with Lys32 of
RAGE, while in the complex for Lys75 all key ionized residues of RAGE
(Lys32, Lys80 and Arg78) are surrounded by HSA residues with which
they can elicit beneﬁcial contacts. Such a comparison seems to conﬁrm
the key role played in RAGE-protein interactions by ion pairs and
suggests that the adducted residues which aﬀord the best interactions
with RAGE are those which are surrounded by electron rich regions.
Clearly, the reported docking results also emphasize the stabilizing role
exerted by H-bonds and other non-ionic contacts, a ﬁnding particularly
evident here considering the neutral state of the simulated adducts.
Nevertheless, the reported complex for Lys499 reveals that, even a
Table 1
AGE-modified peptides identified by MS analysis in high MW-species of BSA-glucose captured by VC1-resin.
Modiﬁcation ΔM Peptide sequencea Amino acidb Charge MH+c ppm
Schiﬀ base +132.04426 AEFVEVTK*LVTDLTK K256 +3 1824.98307 −0.60
Deoxy-fructosyl-lysine +162.05282 ATEEQLK*TVMENFVAFVDK K568 +3 2361.15543 +0.97
QNCDQFEK*LGEYGFQNALIVR K420 +3 2691.27079 −0.45
ADLAK*YICDNQDTISSK K285 +3 2103.97409 −0.49
AEFVEVTK*LVTDLTK K256 +3 1854.99442 −0.17
SLHTLFGDELCK*VASLR K100 +4 2108.06777 −0.73
K*VPQVSTPTLVEVSR K437 +3 1801.98758 −1.70
NYQEAK*DAFLGSFLYEYSR K346 +3 2463.13309 −0.82
Tetra-hydro-pyridmidine +144.04226 YTR*KVPQVSTPTLVEVSR R436 +3 2204.19156 −0.21
Carboxymethyl +58.00548 AFDEK*LFTFHADICTLPDTEK K528 +3 2556.19626 −0.05
AEFVEVTK*LVTDLTK K256 +2 1750.94621 −0.67
HLVDEPQNLIK*QNCDQFEK K412 +3 2413.14438 −0.40
LVNELTEFAK*TCVADESHAGCEK K75 +3 2666.20639 −0.37
LSQK*FPKAEFVEVTK K245 +3 1808.97855 −0.45
K*QTALVELLK K548 +3 1200.72013 +0.21
K*VPQVSTPTLVEVSR K437 +3 1697.94120 −1.24
Carboxyethyl +72.02113 R*HPEYAVSVLLR R360 +3 1511.83170 −0.82
The high MW species of BSA-Glucose (≥250 kDa) shown in Fig. 3A were subjected to in-gel digestion.
a The K* or R* indicate the position of the modiﬁed residue.
b The numbering refers to the amino acid residue in the sequence of the precursor of BSA (containing the signal peptide).
c Experimentally determined monoisotopic mass.
Table 2
AGE-modified peptides identified by MS analysis in high MW-species BSA-ribose captured by VC1-resin.
Modiﬁcation ΔM Peptide sequencea Amino acidb Charge MH+c ppm
Carboxymethyl +58.00548 R*HPEYAVSVLLR R360 +3 1497.81552 −1.18
Pyrraline-derived +78.01056 K*VPQVSTPTLVEVSR K437 +3 1717.94822 −0.10
ALK*AWSVAR K235 +3 1079.59861 −1.01
FPK*AEFVEVTK K248 +3 1372.71704 +1.64
Schiﬀ base +132.04426 K*VPQVSTPTLVEVSR K437 +3 1771.98740 +3.00
ALK*AWSVAR K235 +3 1133.62992 −3.06
R*HPEYAVSVLLR R360 +3 1571.85331 −1.76
Unknown +218.07903 K*VPQVSTPTLVEVSR K437 +3 1858.01419 −1.43
K*QTALVELLK K548 +3 1360.79386 +0.32
R*HPEYAVSVLLR R360 +3 1657.89438 +2.14
Methyl imidazolone +54.01056 YLYEIAR*R R167 +3 1137.60450 −0.57
Carboxyethyl +72.02113 K*VPQVSTPTLVEVSR K437 +3 1711.95627 −1.57
FK*DLGEEHFK K36 +3 1321.64435 +1.51
The high MW species of BSA-ribose (≥250 kDa) shown in Fig. 3B were subjected to in-gel digestion.
a The K* or R* indicate the position of the modiﬁed residue.
b The numbering refers to the amino acid residue in the sequence of the precursor BSA that includes the signal peptide.
c Experimentally determined monoisotopic mass.
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single ionic repulsion is conceivably so penalizing as to prevent the
stabilization of a suitable complex regardless of the number of elicited
H-bonds.
4. Discussion
In this report, we described the use of VC1 domain of hRAGE to set
up a pull-down assay and its successful validation in binding AGE-
modiﬁed proteins. VC1 was designed to bind a streptavidin coated-
resin through the C-terminal Strep tag in order to orient the N-terminal
portion of the V domain to freely interact with the ligands. This tag
permits the use of metallic ions to be avoided since it has been
previously reported that AGE-BSA provides sites for metal-binding
and therefore binding to Ni-resin, independently of VC1, can occur
[29]. Moreover, this aﬃnity assay exploits the higher stability and
solubility of the glycosylated VC1 domain expressed in P. pastoris
compared to the forms produced intracellularly in bacteria. The VC1
pull-down experiments described in this work show that physiologi-
cally relevant and well known RAGE ligands, such as AGE-modiﬁed
serum albumins prepared by incubating the protein with two reducing
sugars (ribose or glucose), are speciﬁcally captured by VC1 domain
while the native forms do not. These results underline both the
selectivity of the resin and the fact that we reached our ﬁrst goal,
which is the set-up of an aﬃnity resin for RAGE binders. Moreover, the
isolation of the protein adducts derived from native and not binder
proteins, also permitted the protein adducts acting as RAGE interactors
to be fully characterized by bottom-up experiments. MS studies
revealed that Lys and Arg residues are the two nucleophilic sites of
BSA undergoing the covalent modiﬁcations and that pyrraline, Schiﬀ
base, and negatively charged moieties, carboxyethyl- and carboxy-
methyl-lysine are the modifying residues. Although a deeper investiga-
tion of the binding mechanism is required, such information strength-
ens the importance of the electrostatic interaction between RAGE and
its binders. In particular, taking into account that the binding surface
of RAGE is positively charged, the identiﬁed modiﬁcations suggest that
the structural features turning a non-protein binder (BSA) to a binder
(AGE-BSA) involve the covalent modiﬁcation of positively charged
residues (Lys and Arg) to form neutral or negatively charged residues
as in the case of the carboxylated residues. We then turned our interest
to understanding whether also ALEs, the protein adducts formed by
lipid peroxidation by-products, can be RAGE binders. MDA was
selected as lipid-peroxidation by-product able to generate ALEs by
reacting with HSA. Our results indicate that also ALE generated by
MDA binds RAGE, providing the ﬁrst evidence that ALE are direct
interactors of VC1. The pull-down experiment was then used to isolate
the HSA-MDA adducts as RAGE binders which were then analyzed by
bottom-up experiments. A comprehensive and original computational
study was performed and applied to the understanding of the experi-
mental results in terms of molecular interactions with the V domain.
Interestingly, the docking results, reported in Table 3, contribute to
explain the interaction of speciﬁc MDA- induced HSA adducts with
RAGE-V domain. One of the “best score” residues is Lys75 of HSA
whose modiﬁed version is predicted to establish ionic contacts and Van
der Waals interaction with Lys32, Gln80 and Arg78 of the V domain. On
opposite a residue with a poor score does not show eﬀective interac-
tions and the presence of repulsion eﬀects are visible in the computed
complex (Fig. 7). Even though a precise validation of the predictive
power of such results would require a clearly wider number of
simulated proteins, the marked score diﬀerences between adducted
and unmodiﬁed residues provide a preliminary validation of the here
applied computational strategy. Even though the speciﬁc contribution
of each adducted residue is unknown, docking results allow a clear
diﬀerentiation between the simulated residues. These docking diﬀer-
ences are reﬂected into meaningful diﬀerences when analysing the
speciﬁc key contacts as seen in the putative complexes (Fig. 7).
Further studies should be carried out to evaluate the binding
capacity of ALEs generated by the diﬀerent RCS generated by lipid
peroxidation and detected in vivo such as acrolein, HNE and GO as
well as AGEs formed by reducing sugar oxidation products such as
MGO.
In conclusion, we here described a double tagged recombinant VC1
domain of hRAGE that can be used to functionalize stationary phases
for aﬃnity chromatography techniques. The application of the VC1-
interaction pull down assay here reported is only in its infancy since
several applications can be considered. The ﬁrst application consists of
isolating and then characterizing RAGE binders from the sera of
subjects aﬀected by diﬀerent pathological conditions and involving an
inﬂammatory condition evoked by RAGE activation, such as diabetes
and atherosclerosis. In view of this application, we tested the selectivity
of the resin by spiking AGE-BSA in human sera and milk. The results
obtained indicate that VC1-resin represents a selective aﬃnity phase
for isolating RAGE binders from complex matrices such as serum and
that it would represent a suitable tool for a functional based enrich-
ment of AGEs and ALEs. This novel enrichment strategy has several
advantages in respect to that based on derivatization and based on
biotin hydrazide or aldehyde/keto reactive probe [7], since it permits
the protein adducts to bind on the basis of their biological interaction
(RAGE ligand) and independently of their structure, as the derivatiza-
tion process does. These studies require a successive validation of the
function by testing the activation of RAGE in cell lines expressing
RAGE and a reporter of the nuclear factor kappa-light-chain-enhancer
of activated B cells (NF-κB) transcription activation.
Further applications of the resin will involve the set-up of high
throughput methods for the measurement of the binding aﬃnities and
Fig. 5. AGE-serum albumin capture by VC1-resin in simulated complex matrices. (A) BSA modiﬁed by incubation with ribose (BSA-R) was added to 5% milk (INPUT) and
the simulated complex matrix was applied to the VC1-resin and to the control resin. (B) HSA modiﬁed by incubation with ribose (HSA-R, ﬁrst lane) was added to human serum (INPUT,
IN second lane) and the simulated complex matrix was applied to VC1-resin or to control resin. Unbound (UNB) and eluted (E) fractions were analyzed by SDS-PAGE, as described in
Fig. 3. The gels show that HMW-species of AGE-serum albumins added to complex matrices are speciﬁcally retained by the VC1-resin.
G. Degani et al. Redox Biology 11 (2017) 275–285
282
Fig. 6. Time course analysis of the dose-dependent modiﬁcation of HSA by MDA. Recombinant HSA was incubated with increasing concentrations of MDA as explained in
Materials and methods. At 24, 48 and 72 h of incubation, aliquots were withdrawn and after removal of free MDA, pull-down assays with the VC1-resin or control (CTRL)-resin were
performed as explained in Fig. 3. A speciﬁc binding of both the monomer of modiﬁed HSA and of the HMW-species to the VC1-resin was detected at increasing concentrations or time of
incubation.
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for the screening of compounds acting as RAGE antagonists, the latter
representing a novel medicinal chemistry approach for the treatment of
several diseases, including Alzheimer's disease, diabetic complications
and chronic inﬂammation [30].
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